These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29196440)

  • 21. Drug delivery and reversal of MDR.
    Huang Y; Li Y
    Mol Pharm; 2014 Aug; 11(8):2493-4. PubMed ID: 25087942
    [No Abstract]   [Full Text] [Related]  

  • 22. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
    Masui K; Gini B; Wykosky J; Zanca C; Mischel PS; Furnari FB; Cavenee WK
    Carcinogenesis; 2013 Apr; 34(4):725-38. PubMed ID: 23455378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.
    Nie L; Rubin EH; Mehrotra N; Pinheiro J; Fernandes LL; Roy A; Bailey S; de Alwis DP
    Clin Cancer Res; 2016 Jun; 22(11):2623-9. PubMed ID: 27250933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
    Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 28. Molecularly targeted therapies: mechanisms of resistance. Abstracts of the AACR (American Association for Cancer Research) Special Conference. May 9-12, 2012. San Diego, California, USA.
    Clin Cancer Res; 2012 May; 18(10 Suppl):A1-68, B1-68, IA1-15, PR1-8. PubMed ID: 23534065
    [No Abstract]   [Full Text] [Related]  

  • 29. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
    Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD
    J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
    Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
    Khleif SN; Doroshow JH; Hait WN;
    Clin Cancer Res; 2010 Jul; 16(13):3299-318. PubMed ID: 20501613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When less is more.
    Kaiser J
    Science; 2017 Mar; 355(6330):1144-1146. PubMed ID: 28302821
    [No Abstract]   [Full Text] [Related]  

  • 38. Mathematical modelling: Forecasting cancer.
    Gammon K
    Nature; 2012 Nov; 491(7425):S66-7. PubMed ID: 23320294
    [No Abstract]   [Full Text] [Related]  

  • 39. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
    Lee H; Hodi FS; Giobbie-Hurder A; Ott PA; Buchbinder EI; Haq R; Tolaney S; Barroso-Sousa R; Zhang K; Donahue H; Davis M; Gargano ME; Kelley KM; Carroll RS; Kaiser UB; Min L
    Cancer Immunol Res; 2017 Dec; 5(12):1133-1140. PubMed ID: 29079654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.